ADC Therapeutics (ADCT) Scheduled to Post Earnings on Thursday

ADC Therapeutics (NYSE:ADCT) is set to release its earnings data before the market opens on Thursday, November 7th. Analysts expect ADC Therapeutics to post earnings of ($0.35) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

ADC Therapeutics (NYSE:ADCT) last posted its earnings results on Tuesday, August 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. The business had revenue of $17.41 million for the quarter, compared to the consensus estimate of $19.06 million. During the same period in the previous year, the firm earned ($0.58) earnings per share. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ADC Therapeutics Stock Performance

ADC Therapeutics stock opened at $3.02 on Wednesday. ADC Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $6.04. The stock has a market cap of $292.00 million, a PE ratio of -1.18 and a beta of 1.59. The firm’s 50-day simple moving average is $3.01 and its 200 day simple moving average is $3.34.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ADCT. Royal Bank of Canada restated an “outperform” rating and set a $8.00 price target on shares of ADC Therapeutics in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of ADC Therapeutics in a research note on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.